德視佳(01846.HK)眼科手術預約量創新高 已達去年全年總量
德視佳(01846.HK)宣佈,截至9月14日,集團今年眼科手術預約量已達去年全年總量,今年首八個月已進行手術總數爲17,330宗,按年增長34.2%,較2019年同期增長36.5%。
按地理位置劃分,德國地區已進行11,265宗手術,按年升約29.4%;中國地區已進行4,262宗手術,升約42%;丹麥地區已進行1,803宗手術,升約49.4%。
德視佳創始人、董事長兼首席執行官約根森表示,新患者手術預約量爲未來眼科手術數目重要的衡量標準,預計將推動收入增長,未來隨着新衛星診所的成立,吸納新患者的能力將進一步加強。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.